Fire fought at Merck plant; FDA seeks injunction against Kabco Pharma;

> Firefighters put out a fire over the weekend at Merck's ($MRK) West Point, PA, plant. Article

> GlaxoSmithKline ($GSK) has struck a deal to have DKSH Healthcare handle its logistics, delivery and collections in Cambodia. Item

> German CMO Temmler Group, which last year hired investment banking firm Lazard to help it find a buyer, is reportedly generating interest from private equity investors. Story

> The FDA says it is seeking an injunction against supplement maker Kabco Pharmaceuticals of Amityville, NY, for not meeting manufacturing standards in the production of products like its dandelion root and vitamin C-500 with rose hips. Release

> A final report from an Indian task force suggesting that all pharmaceuticals carry a unique identifier to protect against counterfeits is awaiting final approval. Story

> Genericsmaker Par Pharmaceuticals has a deal valued at $1.9 billion to be acquired by investment banking firm TPG that can be canceled if it receives a better offer before closing at the end of the year. Story

> Australia's Therapeutic Goods Administration is implementing a 5.6% fee increase on drugmakers to fund a host of reforms proposed last year, which includes publication of inspection and compliance actions. Story

And Finally... In a situation that illustrates the difficulties of maintaining adequate global supplies of some drugs, India is seeking permission to destroy 27 million doses of expired BCG tuberculosis vaccine even as other countries are trying to prevent a shortage of the treatment. Story

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.